Drug Trial Radar · NCT07199777
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 2025
Primary completion
Nov 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- SciNeuroIndustry
- Sponsor type
- Industry
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
Conditions
- Diabetic Macular Edema
- DME
Interventions
SNP318Drug
Once daily, oral administration
PlaceboDrug
Once daily, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EventsTime frame: 12 weeks
- Central Subfield Thickness (CST)Time frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.